Aptus Capital Advisors’s GSK GSK Stock Holding History

Aptus Capital Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$645K	Buy	12,300 +5,059	+70%	+$268K	﹤0.01%	721
2026 Q1	$400K	Sell	7,241 -175	-2%	-$9.48K	﹤0.01%	784
2025 Q4	$364K	Sell	7,416 -73	-1%	-$3.4K	﹤0.01%	831
2025 Q3	$323K	Sell	7,489 -716	-9%	-$28K	﹤0.01%	822
2025 Q2	$315K	Buy	8,205 +1,426	+21%	+$54.5K	﹤0.01%	808
2025 Q1	$263K	Sell	6,779 -236	-3%	-$8.64K	﹤0.01%	807
2024 Q4	$240K	Sell	7,015 -871	-11%	-$31.4K	﹤0.01%	836
2024 Q3	$322K	Buy	7,886 +2,365	+43%	+$96.8K	﹤0.01%	644
2024 Q2	$213K	Buy	5,521 +646	+13%	+$27.2K	﹤0.01%	721
2024 Q1	$209K	Buy	+4,875	New	+$201K	﹤0.01%	721
2020 Q1	–	Sell	-57,718	Closed	-$3.39M	–	449
2019 Q4	$3.39M	Buy	57,718 +10,444	+22%	+$581K	0.24%	71
2019 Q3	$2.52M	Buy	+47,274	New	+$2.43M	0.14%	92

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Aptus Capital Advisors's GSK Position: Q2 2026 in Review

Aptus Capital Advisors increased its GSK (GSK) stake by 70% in Q2 2026, buying an estimated $268K and bringing the position to 12,300 shares worth $645K. The position accounts for ﹤0.01% of the portfolio, ranked #721.

Aptus Capital Advisors first reported a position in GSK in Q3 2019 and has held it in 12 quarters since. The position peaked at $3.39M in Q4 2019. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Aptus Capital Advisors held 12,300 shares of GSK worth $645K as of Q2 2026.
Aptus Capital Advisors bought 5,059 GSK shares in Q2 2026, an estimated $268K.
GSK made up ﹤0.01% of Aptus Capital Advisors's portfolio in Q2 2026, its #721 holding.
Aptus Capital Advisors first reported a position in GSK in Q3 2019 and has held it in 12 quarters since.
Aptus Capital Advisors's GSK position peaked at $3.39M in Q4 2019.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Aptus Capital Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.